BioStar Capital: Robotics Investor Profile

Who BioStar Capital is

BioStar runs five venture funds that invest mainly in cardiology, orthopedics, and robotics, and draws on more than 100 practicing clinicians to vet deals.² Its portfolio company Amplitude Vascular Systems was acquired by Stryker.¹

BioStar was an early investor in Corindus Vascular Robotics, which Siemens Healthineers bought for $1.1 billion in 2019. Corindus chief executive Mark Toland joined BioStar as a partner in 2020 and became MMI's CEO in 2021.^3,4

Deals this month

Robotics bet this month

BioStar first invested in MMI in its 2022 Series B and co-led the extension that followed. On October 8, 2026, it led MMI's $125 million Series D, which MMI says was oversubscribed. Founder Louis Cannon sits on MMI's board.^5,7,6

The thesis is that robotic microsurgery can open procedures, such as lymphatic surgery, that few surgeons can do by hand. The caveat is scale: MMI has about 50 systems installed, so this is a bet on adoption that has not happened yet.⁷

Sources